Allergan 100 Vials - Allergan Refresh Plus Lubricant Eye Drops Single-Use Vials - 100 Ct.

Product Information

To avoid eye injury and contamination, do not let the tip of the dropper touch your eye or anything else. Heart failure; irregularity or stopping of the heartbeat; slow or fast heartbeat; too much fluid, mainly water, accumulating in the body; chest pain The manufacturer, Kilitch Healthcare India Limited, has issued a voluntary recall for these products. FDA recommends confirming the products on the list the agency provided. There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products.

PRED FORTE suspension contains sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people.

The following adverse reactions have been identified during use of PRED FORTE. Because reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. punctate keratitis, eye irritation, eye pruritus, growth of eyelashes, eye pain, erythema of eyelid, eyelid pruritus Rare cases of retinal detachment and retinal tear have been reported with miotics, including VUITY. Individuals with pre-existing retinal disease are at increased risk. Therefore, examination of the retina is advised in all patients prior to the initiation of therapy. Patients should be advised to seek immediate medical care with sudden onset of flashing lights, floaters, or vision loss. Adverse reactions reported by greater than 2% of patients in the first 6 months following injection of OZURDEX ® for retinal vein occlusion and posterior segment uveitis include: intraocular pressure increased (25%), conjunctival hemorrhage (22%), eye pain (8%), conjunctival hyperemia (7%), ocular hypertension (5%), cataract (5%), vitreous detachment (2%), and headache (4%). Increased Bleeding Time: With some NSAIDs, there exists the potential for increased bleeding time due to interference with thrombocyte aggregation. There have been reports that ocularly applied nonsteroidal anti-inflammatory drugs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery. ACUVAIL solution should be used with caution in patients with known bleeding tendencies or who are receiving other medications, which may prolong bleeding time.

Potentiation of Vascular Insufficiency: ALPHAGAN ® P may potentiate syndromes associated with vascular insufficiency. ALPHAGAN ® P should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or thromboangiitis obliterans. FDA recommended the manufacturer of these products recall all lots on October 25, 2023, after agency investigators found insanitary conditions in the manufacturing facility and positive bacterial test results from environmental sampling of critical drug production areas in the facility. FDA also recommends consumers properly discard these products. It’s been a bad year for eye drops. The U.S. Food and Drug Administration (FDA) has issued yet another eye drop recall—this time focusing on 27 different over-the-counter products over concerns about the potential risk of eye infections that could lead to partial vision loss or blindness.Cataracts and Cataract Surgery: The incidence of cataract development in patients who had a phakic study eye was higher in the OZURDEX ® group (68%) compared with Sham (21%). The median time of cataract being reported as an adverse event was approximately 15 months in the OZURDEX® group and 12 months in the Sham group. Among these patients, 61% of OZURDEX ® subjects versus 8% of sham-controlled subjects underwent cataract surgery, generally between Month 18 and Month 39 (Median Month 21 for OZURDEX ® group and 20 for Sham) of the studies. The biggest concern is about post-infection corneal scarring, Zimmerman says. “This scarring can substantially impair vision and may result in a corneal transplant,” he points out. “If identified early and proper treatment occurs, then the risk of post-infectious scarring is much lower than if it were delayed.” Side effects related to the cornea (the surface of the eye) may be more likely if ACULAR is used for longer than two weeks or if you are using topical steroid drops at the same time or if you have a related eye condition. You should see your doctor immediately if you experience pain, increased irritation in the eye or changes in vision. Corneal Endothelial Cell Injury: ZYMAXID is for topical ophthalmic use. ZYMAXID may cause corneal endothelial cell injury if introduced directly into the anterior chamber of the eye. Nursing Mothers: It is not known whether topical ophthalmic administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Because of the potential for serious adverse reactions in nursing infants from prednisolone, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.